Related Experiment Video
Updated: Jun 18, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
Published on: June 18, 2020
Risk factors for treatment failures in antineutrophil cytoplasmic antibody- associated small-vessel vasculitis
Vijay R Karia1, Luis R Espinoza
1Department of Internal Medicine, Section of Rheumatology, Louisiana State University Health Sciences Center at New Orleans, 1542 Tulane Avenue, New Orleans, LA 70112, USA.
Abstract:
In the past several years, significant progress has occurred in the therapeutic management of antineutrophil cytoplasmic antibody-associated vasculitis. This has resulted in improved survival rates for all members of this group of inflammatory vascular disorders. However, the rate of treatment failure or resistance and relapse has remained relatively constant despite therapeutic advances. This article reviews risk factors associated with these failures, with hopes that better understanding may lead to improved therapeutic responses and less therapy-related toxicity.
Related Concept Videos
Drug Toxicity: Risk factors
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Venous Thrombosis III: Interprofessional Care